Insider Selling: Outset Medical (NASDAQ:OM) CEO Sells 3,445 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,445 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $3.70, for a total value of $12,746.50. Following the completion of the sale, the chief executive officer owned 98,874 shares of the company’s stock, valued at $365,833.80. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

OM traded up $0.14 during trading on Tuesday, reaching $3.86. The stock had a trading volume of 119,135 shares, compared to its average volume of 171,183. The firm has a market capitalization of $71.56 million, a price-to-earnings ratio of -0.93 and a beta of 1.92. The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87. Outset Medical, Inc. has a 1-year low of $3.00 and a 1-year high of $21.98. The stock has a 50 day moving average of $3.94 and a two-hundred day moving average of $4.63.

Outset Medical (NASDAQ:OM) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The firm had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. As a group, equities analysts anticipate that Outset Medical, Inc. will post -3.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. BTIG Research reduced their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Outset Medical has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Trading of Outset Medical

Hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC purchased a new stake in shares of Outset Medical in the fourth quarter valued at $29,000. Legal & General Group Plc purchased a new stake in shares of Outset Medical in the second quarter valued at $34,000. BNP Paribas Financial Markets lifted its holdings in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Outset Medical in the fourth quarter valued at $46,000. Finally, HRT Financial LP purchased a new stake in shares of Outset Medical in the fourth quarter valued at $58,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.